ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, as amended, was submitted through a correspondence filed via EDGAR. The company, based in Weston, Florida, has indicated that the effective date and time are subject to change if they notify the SEC otherwise. ZyVersa's CEO, Stephen C. Glover, signed the request, and the company's outside counsel, Faith L. Charles of Thompson Hine LLP, is the point of contact for any inquiries related to this matter.

ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, as amended, was submitted through a correspondence filed via EDGAR. The company, based in Weston, Florida, has indicated that the effective date and time are subject to change if they notify the SEC otherwise. ZyVersa's CEO, Stephen C. Glover, signed the request, and the company's outside counsel, Faith L. Charles of Thompson Hine LLP, is the point of contact for any inquiries related to this matter.